Figure 1 — TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types | Aging

Navigate

Submit an Article

Research Paper|Volume 14, Issue 6|pp. 2868–2879

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types

Back to articleFigure 1(1 of 4)

100%

Figure 1.Prevalence of TP53/BRAF mutations in pan-cancer.